Research Topics for ACR Using TriNetX Database
Focus your rheumatology research using TriNetX on comparative effectiveness, safety surveillance, and health disparities studies that leverage the platform's large-scale electronic health record data to answer questions impractical for traditional RCTs.
Why TriNetX for Rheumatology Research
TriNetX provides access to over 150 million electronic health records across a federated network, making it particularly valuable for rheumatology research where rare outcomes, diverse populations, and long-term safety monitoring are critical 1. The platform's real-time, privacy-compliant data access allows retrospective studies that complement traditional clinical trials, especially for questions involving rare diseases, uncommon adverse events, and underrepresented patient populations 1.
The Dataworks-USA Network is broadly generalizable to the US healthcare-seeking population, though it skews slightly older (approximately 5 years) and has a higher proportion of female patients compared to Census data 2. Regional and racial representation varies, with lower proportions of Asian and White patients and higher proportions of "Other" race categories due to data capture limitations 2.
High-Priority Research Topics
1. Treatment Safety in High-Risk Populations
Examine DMARD and biologic safety in patients with hepatitis, congestive heart failure, malignancy, and serious infections 3, 4. The 2015 ACR guidelines identify these as critical knowledge gaps, and TriNetX's large sample size enables detection of rare adverse events that RCTs are underpowered to identify 1.
Specific research questions:
- Comparative risk of hepatitis reactivation across different biologic classes
- Heart failure exacerbation rates with TNF inhibitors versus non-TNF biologics
- Cancer recurrence rates in patients with prior malignancy starting biologics
- Serious infection rates stratified by comorbidity burden and immunosuppression intensity
2. COVID-19 and Rheumatic Disease Outcomes
Investigate temporal trends in COVID-19 outcomes, vaccination responses, and medication management strategies in rheumatic disease populations 5. The ACR COVID-19 guidance acknowledges substantial knowledge gaps regarding optimal medication management during infection and recovery 5.
Priority questions:
- Timing of medication restart after COVID-19 recovery stratified by disease type and severity
- Comparative COVID-19 outcomes across different immunosuppressive regimens
- Breakthrough infection rates and severity post-vaccination by medication class
- Long COVID prevalence and risk factors in rheumatic disease populations
A prior TriNetX study demonstrated improved COVID-19 outcomes over time in rheumatic disease patients, but substantial risks remain 6. Build on this by examining medication-specific risks and protective factors.
3. Comparative Effectiveness of Treatment Sequences
Analyze real-world treatment sequences and switching patterns to inform optimal therapeutic algorithms 3, 4. The 2015 ACR guidelines provide treatment algorithms but acknowledge limited evidence for optimal sequencing, particularly after initial biologic failure 3.
Key research areas:
- Effectiveness of switching from TNF inhibitor to another TNF inhibitor versus switching to non-TNF biologic
- Optimal timing for treatment escalation based on disease activity trajectories
- Comparative effectiveness of triple DMARD therapy versus biologic monotherapy in early RA
- Real-world adherence and persistence patterns across different medication classes
4. Health Disparities and Access to Care
Examine racial, ethnic, geographic, and socioeconomic disparities in treatment access, disease outcomes, and quality of care 7, 2. TriNetX's diverse patient population enables robust disparity analyses, though attention to missing race/ethnicity data is essential 2.
Research priorities:
- Time to biologic initiation stratified by race, ethnicity, and insurance status
- Geographic variation in treat-to-target implementation and disease activity control
- Disparities in preventive care (vaccinations, TB screening, laboratory monitoring)
- Social determinants of health impact on treatment adherence and outcomes
5. Rare Adverse Events and Long-Term Safety
Conduct pharmacovigilance studies for rare but serious adverse events that require large sample sizes 1, 8. TriNetX excels at detecting signals for uncommon outcomes across diverse patient populations 1.
Focus areas:
- Malignancy risk with JAK inhibitors versus biologics in real-world populations
- Cardiovascular event rates across different biologic classes
- Progressive multifocal leukoencephalopathy risk factors in rituximab-treated patients
- Interstitial lung disease progression with different DMARDs in rheumatoid arthritis
6. Predictors of Disease Progression in At-Risk Populations
Identify biomarkers and risk factors predicting progression from at-risk states to clinical rheumatoid arthritis 7. The 2021 EULAR points to consider highlight critical knowledge gaps in understanding progression pathways and optimal intervention timing 7.
Research questions:
- Sequence and timescale of biomarker changes preceding RA diagnosis
- Impact of comorbidities (periodontal disease, obesity, smoking) on progression risk
- Subclinical inflammation patterns predicting clinical disease development
- Effectiveness of early intervention in high-risk seropositive individuals
7. Glucocorticoid Use Patterns and Outcomes
Examine real-world glucocorticoid prescribing patterns, tapering strategies, and associated adverse events 3. Despite widespread use, optimal dosing and duration remain controversial 3.
Priority analyses:
- Dose-response relationships for adverse events (infections, cardiovascular events, fractures)
- Effectiveness of different tapering protocols on disease flare rates
- Long-term outcomes comparing glucocorticoid-sparing versus glucocorticoid-inclusive strategies
- Predictors of successful glucocorticoid discontinuation
8. Vaccination Responses and Infection Risk
Analyze vaccination uptake, timing relative to immunosuppression, and breakthrough infection rates 3, 4. The ACR guidelines emphasize vaccination importance but acknowledge limited real-world implementation data 3, 4.
Key questions:
- Optimal timing of vaccinations relative to biologic administration
- Comparative infection rates in vaccinated versus unvaccinated patients on immunosuppression
- Predictors of vaccine hesitancy in rheumatic disease populations
- Effectiveness of different vaccination strategies (live versus inactivated vaccines)
Methodological Considerations
Strengths of TriNetX for These Topics
- Large sample size enables rare outcome detection and subgroup analyses 1
- Diverse patient populations improve generalizability beyond RCT populations 1, 2
- Real-time data access allows rapid hypothesis testing and surveillance 1
- Federated network architecture maintains privacy while enabling multi-site collaboration 1, 9
Critical Limitations to Address
- Missing data particularly for race/ethnicity, laboratory values, and disease activity measures 10, 2
- Confounding by indication requires robust propensity score matching or instrumental variable approaches 10, 8
- Data quality variability across contributing healthcare organizations necessitates sensitivity analyses 10
- Lack of standardized disease activity measures limits treat-to-target research 10, 8
Best Practices for Study Design
Use exposure score matching or propensity score methods to control for confounding 6, 10. The temporal trends COVID-19 study successfully employed exposure score matching for demographics, comorbidities, and prior healthcare utilization 6.
Conduct sensitivity analyses to assess robustness of findings to missing data and unmeasured confounding 10, 8. Test assumptions about data completeness and quality across different healthcare organizations 10.
Link TriNetX data with other sources when possible to enhance data richness, such as patient registries for disease activity measures or claims data for medication adherence 8.
Validate findings using external datasets or published literature to ensure reproducibility and generalizability 10.
Alignment with ACR Priorities
These research topics directly address knowledge gaps identified in ACR guidelines 3, 4, 5 while leveraging TriNetX's unique strengths for large-scale observational research 1. The platform's ability to rapidly generate real-world evidence complements traditional RCTs and supports the ACR's commitment to evidence-based, patient-centered care 3.
Prioritize studies that impact morbidity, mortality, and quality of life rather than surrogate endpoints alone. Focus on patient-relevant outcomes including hospitalizations, serious infections, cardiovascular events, functional status, and mortality 3.